Vaxcyte advances VAX-31 as Phase 3 trial design choices highlight regulatory and adoption priorities
Vaxcyte advances VAX-31 into pivotal adult and infant studies. Find out how trial design choices shape regulatory and adoption outcomes.
Pharma & Biotech
Pharma & Biotech
How amlitelimab’s dosing flexibility could disrupt biologic treatment patterns in atopic dermatitis
Sanofi’s amlitelimab advances toward filing in atopic dermatitis. Explore how dosing flexibility, durability data, and regional results shape its outlook.
Pharma & Biotech
How PDS0101 patent coverage reshapes competitive risk in HPV16 positive head and neck cancer development
PDS Biotechnology strengthens PDS0101 patent protection as Phase 3 strategy evolves. Discover what this changes for immunotherapy competition.
Medical Devices & Diagnostics
Why 60 Degrees Pharmaceuticals is betting on Runway Health to reshape malaria prevention access
Discover how 60 Degrees Pharmaceuticals is using telehealth to expand ARAKODA access and what this shift means for malaria prevention strategy.
Medical Devices & Diagnostics
BioTissue divests surgical and wound care business to BioStem, sharpening focus on ocular regeneration
BioTissue Holdings, Inc. has completed the divestiture of its non-ocular surgical and wound care business to BioStem Technologies, Inc. in a transaction valued at approximately $15 million upfront, with potential earnouts tied to regulatory and commercial milestones. The deal transfers ownership of the Neox and Clarix product lines, along with a seasoned commercial team and
Medical Devices & Diagnostics
Lucid Diagnostics gains strategic VA partnership to deploy EsoGuard across veteran programs
Discover how Lucid Diagnostics is expanding EsoGuard adoption with a new U.S. Veterans Affairs contract for early cancer screening.
Pharma & Biotech
INTENT Biologics secures FDA pediatric waiver, clears path to late-stage DFU trial for PEP Biologic
The U.S. Food and Drug Administration (FDA) has granted INTENT Biologics a full pediatric study waiver for its lead candidate, PEP Biologic, under IND 019567. The waiver, part of an agreed Initial Pediatric Study Plan (iPSP), applies to the product’s adult-focused development for diabetic foot ulcers (DFUs), a serious chronic wound indication preparing for pivotal
Pharma & Biotech
Insilico, Hygtia Therapeutics to co-develop brain-penetrant NLRP3 inhibitor ISM8969 for CNS diseases
Clinical-stage biotechnology company Insilico Medicine (HKEX: 3696) and Hygtia Therapeutics, a Shenzhen Pengfu Fund–backed startup under Fosun Health Capital, have entered into an exclusive co-development and licensing agreement to jointly advance ISM8969, a novel brain-penetrant NLRP3 inhibitor for central nervous system diseases. The deal grants 50-50 worldwide rights to both companies, with Insilico eligible to
Pharma & Biotech
Adaptin Bio prepares Phase 1 glioblastoma trial following preclinical progress in brain cancer candidate
Find out how Adaptin Bio is preparing a Phase 1 glioblastoma trial and why its preclinical progress matters for brain cancer treatment innovation.
Pharma & Biotech
MAIA Biotechnology advances ateganosine cancer program with Phase 3 THIO-104 trial and 2026 catalyst timeline
Find out how MAIA Biotechnology is advancing ateganosine into Phase 3 and why its 2026 clinical milestones could reshape treatment options in lung cancer.